| Literature DB >> 29093313 |
Laura Navika Yamani1, Yoshihiko Yano2,3, Takako Utsumi1,2, Widya Wasityastuti4, Hanggoro Tri Rinonce5, Dewiyani Indah Widasari5, Maria Inge Lusida1, Yoshitake Hayashi2.
Abstract
Mutations in the reverse transcriptase (RT) region of the hepatitis B virus (HBV) genome are an important factor in low therapeutic effectiveness. Nonetheless, the prevalence of these mutations in HBV strains isolated previously in Indonesia has not been systematically examined. Therefore, in this study, we investigated the profile of mutations in the RT region and the associations of these mutations with amino acid changes in the surface protein in the virus of treatment-naïve Indonesian HBV carriers. Overall, 96 sequences of the full-length Indonesian HBV genomes (genotype B, n = 54; genotype C, n = 42) were retrieved from the National Center for Biotechnology Information. Naturally occurring primary and/or compensatory drug resistance mutations were found in 6/54 (11.1%) genotype B strains and in 1/42 (2.4%) genotype C strains. The potential mutations underlying resistance to a nucleos(t)ide analog and/or pretreatment mutations were more frequent in both genotypes but more frequent in genotype C strains than in genotype B strains. The A-B interdomain region in the RT gene was more frequently mutated in genotype C than in genotype B (3.51 ± 2.53 vs. 1.08 ± 1.52, P < 0.001). Knowledge about the mutational profiles of the RT gene and changes in the surface protein may help clinicians to select the most appropriate antiviral drug and vaccination or HBV immunoglobulin regimen for management of HBV infection in Indonesia.Entities:
Keywords: Indonesia; hepatitis B virus (HBV); nucleos(t)ide analog (NA) resistance; reverse transcriptase (RT) gene
Mesh:
Substances:
Year: 2017 PMID: 29093313 DOI: 10.7883/yoken.JJID.2017.078
Source DB: PubMed Journal: Jpn J Infect Dis ISSN: 1344-6304 Impact factor: 1.362